Skip to content
  • YouTube
  • Facebook
  • LinkedIn
Pharm'Up

Pharm'Up

An E-platform for Learners

https://www.youtube.com/watch?v=xuTKPPZrxy4
Primary Menu
  • Home
  • News
  • Industries
  • Disease
  • Drugs
  • Events
  • Jobs
  • Trainings
  • Conferences
  • Syllabus
  • Previous Papers
  • Notes
  • Colleges
Live
  • Home
  • 2025
  • August
  • 21
  • Study Links Childhood COVID-19 to Heightened Long-Term Cardiovascular Risk
  • Pharma News

Study Links Childhood COVID-19 to Heightened Long-Term Cardiovascular Risk

Pharm'Up 2 min read

A groundbreaking study published in the Journal of Proteome Research has challenged the long-held assumption that children are largely immune to the serious, long-term health consequences of COVID-19. Researchers from Harvard and Murdoch University have identified significant metabolic disruptions in children who have had SARS-CoV-2 infections, with a particularly marked impact on those who developed Multisystem Inflammatory Syndrome in Children (MIS-C). These metabolic shifts are closely associated with established risk factors for cardiovascular disease, raising serious concerns about future health complications.

While children generally experience milder respiratory symptoms from COVID-19 compared to adults, they are uniquely susceptible to MIS-C, a rare but severe hyperinflammatory syndrome that typically emerges weeks after an initial infection. Previous research had already linked MIS-C to short-term complications and long-term issues, including severe gastrointestinal symptoms and cardiovascular injury. This new study provides crucial molecular evidence of these long-term risks.

Deep Metabolic Profiling Reveals Concerning Patterns

The investigators conducted the largest-ever metabolic profiling study on children following SARS-CoV-2 infection, analyzing blood samples from 147 children across three groups: those with acute COVID-19, those with MIS-C, and a healthy control group. By performing deep metabolic phenotyping on over 1,100 metabolites, they found that both the COVID-19 and MIS-C cohorts exhibited distinct metabolic profiles compared to the healthy children.

A central finding was the significant shifts in lipid classes—fats in the blood—that are directly tied to cardiovascular health. The study revealed consistent increases in the Apo-B100/Apo-A1 ratio, a well-known predictive marker for atherosclerosis and future heart disease. Additionally, the researchers observed elevated triglycerides and changes in both high-density lipoprotein (HDL) and low-density lipoprotein (LDL) parameters in the infected children.

A Molecular Bridge Between Pediatric and Adult Infection

Perhaps most critically, the study demonstrated a strong similarity in metabolic perturbations between children with COVID-19 and adults who have had the virus, despite the children’s milder clinical symptoms. The inflammatory markers observed in adult patients—such as altered glutamine-to-glutamate ratios and elevated systemic inflammatory biomarkers—were consistently found in the pediatric cohorts as well.

The authors concluded that while children might be better at maintaining metabolic stability during acute infection, the persistence of these inflammatory and cardiovascular markers poses a tangible risk for long-term health. The patients with MIS-C were the most severely affected, showing the most pronounced metabolic alterations. This study serves as a stark warning, highlighting a potential silent epidemic of long-term cardiovascular issues stemming from childhood COVID-19 infections. The investigators stressed the urgent need for further research to fully understand these lasting impacts and develop appropriate long-term monitoring and care strategies for affected children.

About the Author

Pharm'Up

Author

An E-platform for Pharma Learners

View All Posts

Post navigation

Previous: FDA Clears Signos as First Over-the-Counter Continuous Glucose Monitor for Weight Management
Next: MET Inhibitor Strategy Bolsters Chemoimmunotherapy, Crushing Treatment Resistance in SCLC Patients

Related Stories

Pharm up 385
2 min read
  • Pharma News

Targeting RNA Modification: FTO Enzyme Emerges as a Biomarker and Therapeutic Target in Gastrointestinal Cancers

Pharm'Up
Pharm up 384
2 min read
  • Pharma News

Advancing Oncology Care: Zydus and Formycon Secure USFDA BLA Acceptance for FYB206, the First Publicly Announced Keytruda Biosimilar

Pharm'Up
Pharm up 383
2 min read
  • Pharma News

Strengthening Regulatory Oversight: India Proposes Strict Advertising Bans on Prescription Drugs for Retailers and Wholesalers

Pharm'Up

Recent Posts

  • Pharmacovigilance Assistant Recruitment: Indian Pharmacopoeia Commission (IPC) Hiring at SVIMS, Tirupati
  • AIIMS Jodhpur Recruitment: Project Research Scientist-I Position in Neurosurgery
  • AYUSH-CCRUM Funded Senior Research Fellow (SRF) Position at INST Mohali
  • Research Fellowships at AIIMS Jodhpur: Openings for Research Associate-III
  • Lupin Limited Walk-In Interview: Production Apprentice Openings for Freshers

Recent Comments

No comments to show.

Archives

  • October 2026
  • September 2026
  • August 2026
  • April 2026
  • March 2026
  • February 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • August 2025
  • July 2025

Categories

  • Colleges
  • Conferences/ Workshops
  • Disease
  • Drugs
  • Events
  • Industries
  • Notes
  • Pharma Jobs
  • Pharma News
  • Previous Papers
  • Syllabus
  • Trainings/ Courses
  • Uncategorized

Read These Too

Pharm up 405
2 min read
  • Pharma Jobs

Pharmacovigilance Assistant Recruitment: Indian Pharmacopoeia Commission (IPC) Hiring at SVIMS, Tirupati

Pharm'Up
Pharm up 403
2 min read
  • Pharma Jobs

AIIMS Jodhpur Recruitment: Project Research Scientist-I Position in Neurosurgery

Pharm'Up
Pharm up 402
1 min read
  • Pharma Jobs

AYUSH-CCRUM Funded Senior Research Fellow (SRF) Position at INST Mohali

Pharm'Up
Pharm up 401
2 min read
  • Pharma Jobs

Research Fellowships at AIIMS Jodhpur: Openings for Research Associate-III

Pharm'Up
  • YouTube
  • Facebook
  • LinkedIn
Copyright ©Pharm'UP All rights reserved by Eduversity India | MoreNews by AF themes.